NelliBejanyanMD

Hematologic Oncology

Program Leader of BMT, Section Head of Leukemia/Myeloid BMT-CI

Overview of Dr. Bejanyan

Dr. Nelli Bejanyan is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and M Health Fairview Southdale Hospital. She received her medical degree from Yerevan State Medical University and has been in practice 18 years. Dr. Bejanyan accepts several types of health insurance, listed below. She is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 54 doctors at M Health Fairview Southdale Hospital who specialize in Oncology. She has more than 90 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(229) 545-5327

Fax+1 813-449-8618

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2009 - 2012
Cleveland Clinic FoundationFellowship, Bone Marrow Failure Diseases , 2008 - 2009
Cleveland Clinic FoundationResidency, Internal Medicine, 2007 - 2008
St Vincent HospitalResidency, Internal Medicine, 2005 - 2007
Yerevan State Medical UniversityClass of 1999

Certifications & Licensure

FL State Medical License 2017 - 2026
MN State Medical License 2012 - 2018
OH State Medical License 2006 - 2013
American Board of Internal Medicine Hematology

Clinical Trials

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Start of enrollment: 2014 Oct 01
Terminated
Not Applicable
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Start of enrollment: 2015 Nov 05
Active, not recruiting
Phase 2
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Start of enrollment: 2017 Jan 24
Active, not recruiting
Phase 2
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.
Piyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, Samer Srour, Brian Shaffer
Transplantation and Cellular Therapy. 2024-12-01
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and ...
Raheel Iftikhar, Zachariah DeFilipp, Amy E DeZern, Michael A Pulsipher, Nelli Bejanyan
Transplantation and Cellular Therapy. 2024-12-01
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
Blood. 2024-11-28

Journal Articles

Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Romiplostim Improves Platelet Recovery after UCB Transplant
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Nelli Bejanyan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Personal Loss Plays ‘Profound Role’ in Shaping Doctor’s Career PathJune 12th, 2024

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open Access
Humana ChoiceCare Network PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment